| Acute Leukemia |
1 |
1 |
| Stem Cell Research and Therapy |
0 |
1 |
| Biologic Therapy |
0 |
0.72 |
| Chronic Myelogenous Leukemia |
0 |
0.72 |
| Refractory |
0 |
0.61 |
| Transplantation |
0 |
0.75 |
| Allograft |
0 |
0.39 |
| Remission |
0 |
0.3 |
| Chemotherapy |
0 |
0.24 |
| Hypertension |
0 |
0.24 |
| Leukemia |
0 |
0.24 |
| Acute Lymphoblastic Leukemia |
0 |
0.22 |
| Non-Hodgkin Lymphoma (NHL) |
0 |
0.21 |
| Cancer |
0 |
0.18 |
| Central Nervous System |
0 |
0.18 |
| Cerebrovascular Accident |
0 |
0.18 |
| Thromboembolism |
0 |
0.18 |
| Myocardial Infarction (MI) |
0 |
0.13 |
| Deep Venous Thrombosis |
0 |
0.11 |
| Aminotransferase |
0 |
0.1 |
| Cardiac Catheterization |
0 |
0.09 |
| Hypovolemic Shock |
0 |
0.09 |
| Polymerase Chain Reaction (PCR) |
0 |
0.09 |
| Tyrosine Kinase Inhibitor |
0 |
0.09 |
| Abdominal Infection |
0 |
0.08 |
| Cardiovascular Risk Management |
0 |
0.08 |
| Dermatitis |
0 |
0.08 |
| Neutropenia |
0 |
0.08 |
| Pancreatitis |
0 |
0.08 |
| Revenue and Practice Management |
0 |
0.08 |
| Blood |
0 |
0.06 |
| Brachial |
0 |
0.06 |
| Cardiovascular disease |
0 |
0.06 |
| Catheterization |
0 |
0.06 |
| Cytokines |
0 |
0.06 |
| Encephalopathy |
0 |
0.06 |
| Europe |
0 |
0.06 |
| Fever |
0 |
0.06 |
| Hematology |
0 |
0.06 |
| Id Reaction |
0 |
0.06 |
| Infarction |
0 |
0.06 |
| Insurance |
0 |
0.06 |
| Ischemia |
0 |
0.06 |
| Liver |
0 |
0.06 |
| Lymphoma |
0 |
0.06 |
| Prophylaxis |
0 |
0.06 |
| Residual Disease |
0 |
0.06 |
| Salvage Therapy |
0 |
0.06 |
| Shock |
0 |
0.06 |
| T-Lymphocyte |
0 |
0.06 |
| Texas |
0 |
0.06 |
| Thrombosis |
0 |
0.06 |
| Tremor |
0 |
0.06 |
| Tyrosine Kinase |
0 |
0.06 |
| Vein |
0 |
0.06 |